Natus Medical Inc. (NASDAQ:BABY) shares traded up 4% on Wednesday . The stock traded as high as $38.44 and last traded at $38.31, with a volume of 411,605 shares. The stock had previously closed at $36.85.

Several research analysts have weighed in on the company. Zacks Investment Research lowered Natus Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, March 29th. Roth Capital reaffirmed a “buy” rating on shares of Natus Medical in a research report on Thursday, April 21st. Finally, Raymond James Financial Inc. lowered Natus Medical from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 5th.

The firm has a market cap of $1.25 billion and a price-to-earnings ratio of 33.61. The firm has a 50-day moving average price of $35.09 and a 200-day moving average price of $36.16.

Natus Medical (NASDAQ:BABY) last released its earnings results on Wednesday, April 20th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.30 by $0.04. The business had revenue of $87.30 million for the quarter, compared to analyst estimates of $90.47 million. During the same period in the prior year, the business earned $0.31 EPS. The company’s revenue for the quarter was down 2.3% on a year-over-year basis. On average, equities research analysts anticipate that Natus Medical Inc. will post $1.64 earnings per share for the current fiscal year.

In other Natus Medical news, Director Doris Engibous sold 5,000 shares of the stock in a transaction that occurred on Friday, April 22nd. The stock was sold at an average price of $32.68, for a total value of $163,400.00. Following the transaction, the director now owns 18,250 shares in the company, valued at $596,410. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Kenneth M. Traverso sold 7,459 shares of the stock in a transaction that occurred on Friday, April 22nd. The stock was sold at an average price of $33.56, for a total value of $250,324.04. Following the completion of the transaction, the vice president now owns 112,119 shares in the company, valued at approximately $3,762,713.64. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently made changes to their positions in the company. Sawtooth Asset Management Inc. raised its position in shares of Natus Medical by 6,178.3% in the fourth quarter. Sawtooth Asset Management Inc. now owns 25,490 shares of the company’s stock valued at $1,225,000 after buying an additional 25,084 shares during the last quarter. Rhumbline Advisers raised its position in shares of Natus Medical by 10.8% in the fourth quarter. Rhumbline Advisers now owns 42,850 shares of the company’s stock valued at $2,059,000 after buying an additional 4,165 shares during the last quarter. Sei Investments Co. raised its position in shares of Natus Medical by 1,021.6% in the fourth quarter. Sei Investments Co. now owns 56,452 shares of the company’s stock valued at $2,712,000 after buying an additional 51,419 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Natus Medical by 12.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 63,516 shares of the company’s stock valued at $3,053,000 after buying an additional 7,125 shares during the last quarter. Finally, Bank of Montreal Can raised its position in shares of Natus Medical by 438.3% in the fourth quarter. Bank of Montreal Can now owns 66,692 shares of the company’s stock valued at $3,205,000 after buying an additional 54,303 shares during the last quarter.

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.